by Bramarambika B | Jul 24, 2026 | Pharma
Quick Overview Launching a new drug has never been more expensive, more scrutinized, or more data-dependent. With a $236 billion patent cliff looming through 2030 and Medicare price negotiations reshaping margins starting in 2026, pharma leaders no longer have the...
by Bramarambika B | Jul 24, 2026 | Pharma
Quick Overview Pharmaceutical leaders are under constant pressure to launch faster, engage HCPs more precisely, and prove market access value with hard numbers — all while commercial teams sit on more data than they can turn into decisions. This is exactly where Life...
by Bramarambika B | Jul 22, 2026 | AI
Bottom Line New York companies looking to adopt AI keep running into the same fork in the road: bring in an AI consulting firm, or hire and build an internal AI team. Consulting firms get a working solution live in weeks and spread industry experience across finance,...
by Bramarambika B | Jul 22, 2026 | AI
What This Guide Covers Enterprise analytics leaders in pharma, retail, and e-commerce are under pressure to turn commercial data into competitive advantage — faster forecasting, sharper segmentation, smarter pricing, and AI-ready pipelines. But the market for AI...
by Bramarambika B | Jul 22, 2026 | AI
Quick Overview Philadelphia businesses evaluating AI adoption face one core decision: hire an AI consulting firm or build an in-house AI team. Consulting firms offer faster deployment, lower upfront risk, and broad cross-industry expertise, while in-house teams offer...
Recent Comments